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Introduction 
 
Gliomas are a heterogeneous group of neoplasms that comprise almost 70% of all primary 
central nervous system (CNS) neoplasms. While these tumours were previously classified on the 
basis of their histology, with the advent of molecular markers that provide enhanced diagnostic 
accuracy and prognostic information, the classification of CNS tumors now includes phenotypic 
and genotypic parameters.  This is evidenced in the 2016 update of the WHO classification of 
CNS tumours which incorporates IDH mutations and 1p/19q co-deletions into the classification 
of gliomas. In recent years it has been found that TERT promoter mutations are of prognostic 
relevance in gliomas.  
 
Objectives  
 
1)To determine the prevalence of TERT promoter mutations in diffuse gliomas of WHO grades 
II, III and IV. 
2) To determine the association of TERT promoter mutations with other molecular alterations in 
diffuse gliomas. 
3) To assess the role of TERT promoter mutations in overall survival and progression free 
survival in relation to histological and molecular glioma subtypes. 
 
Materials and methods 
  
All gliomas of WHO grade II, III and IV diagnosed in the Department of General Pathology in 
the time period January 1st 2009 to January 2012 that had tissue in the tumour bank were traced 
in the registry. Clinical details of these patients was retrieved that included age, gender, size, 
presenting symptoms, MRI features, location of tumor surgical treatment given, chemotherapy 
status, radiotherapy status, recurrence and death. 
The histological features of each of these cases was reviewed. For those cases that had not had 
the complete panel of ancillary tests for arriving at a specific diagnosis, representative slides 
were selected and sections cut from their corresponding paraffin blocks. 2 to 3-micron thick 
sections from these selected paraffin blocks were cut and mounted on Poly-L lysine coated for 
immunohistochemistry for IDH-1 mutation and ATRX mutation and FISH for 1p/19q co-
deletions. PCR sequencing for TERT promoter mutation.  Five glioma molecular sub groups of 
gliomas were defined using three molecular alterations - TERT promoter mutations, IDH 
mutation, and 1p/19q codeletion.  The molecular sub-groups were: i) IDH mutations only, ii) 
IDH and TERT mutations only, iii) IDH and 1p/19q co-deletion only, iv) Triple negative and v) 
Triple positive.   
 
 
Results 
 
A cohort of 107 adult patients with diffuse gliomas, WHO grades II-IV, formed the study group  
IDH mutations were seen in 62% of diffuse gliomas, and their presence was significantly 
associated with a better progression free and overall survival(p=0.001). 1p/19q co-deletions were 
significantly associated with better overall and progression free survival (p=0.028). TERT 
promoter mutations were seen in 47.6% and occurred frequently in Anaplastic 
oligodendrogliomas (94%), Oligodendrogliomas (87.5%) and Glioblastomas (54%). There was 
no statistical correlation seen between TERT promoter mutations and survival. However, 
analysis of the molecular sub-groups showed that the triple positive tumours carried the best 
prognosis, followed by ‘IDH only’, triple negative and finally ‘TERT only’ tumours (p-value 
<0.000). 
 
Conclusion 
 
 Sub-classification of diffuse gliomas using molecular markers, TERT promoter mutations, IDH 
mutation, and 1p/19q codeletion, separates them into prognostically relevant categories 
 
 
